Acetyl-L-Carnitine Boosts Effectiveness of Alzheimer's Treatments

A new study indicates that Acetyl-L-carnitine (ALC) can help improve cognitive function, ability to function, and behavioral symptoms in Alzheimers patients who had not responded to treatment with acetylcholinesterase inhibitors (AChE-I).

Past studies have shown that ALC has nerve-protective properties and it has recently been shown to reduce attention deficits in patients with Alzheimers disease after long-term treatment.

In the current study, researchers evaluated the effects of 2 grams daily of oral ALC for 3 months in 23 patients with mild Alzheimers. The subjects also took their standard Alzheimers medications, donepezil or rivastigmine. Study subjects had not responded to treatment with acetylcholinesterase inhibitors (AChE-I).

Researchers evaluated the efficacy of ALC by assessing the level of improvement in cognitive functions, functional status and behavioral symptoms. When the patients had been given AChE-I treatment without the ALC, 38% of the subjects improved. After treatment with ALC, 50% of the Alzheimers patients experienced improvement. The researchers concluded that combining ALC with traditional treatments may be a useful therapeutic option in Alzheimers patients.

How did we qualify VRP?

Reference:
Bianchetti, A, Rozzini R, Trabucchi M. Effects of Acetyl-L-Carnitine In Alzheimers Disease Patients Unresponsive to Acetylcholinesterase Inhibitors. Curr Med Res Opin. 2003; 19(4):350-353.

This study indicates that people at risk for Alzheimers disease and Alzheimers disease patients may benefit from VRPs Acetyl-L-Carnitine supplements.

Binaural Beat Brainwave Entrainment Audio Technology | Advanced Human Biochemical Enhancement